Trial 7H-12-4


A Randomized Phase II Trial of ARQ 197 (Tivantinib)/Cetuximab versus Cetuximab in Patients with Recurrent/Metastatic Head and Neck Cancer.

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Charlean Ketchens, R.N., Lagrimas Ilagan, D.M., Gina Tse, R.N., Eduardo Mejia, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.